Farnesol (Acyclic Sesquiterpene Alcohol · Anti-biofilm · Candida Quorum Sensing · Antimicrobial)
| Compound | Farnesol |
| Chemical class | Terpenoid — Acyclic Sesquiterpene Alcohol (C15) |
| CAS | 4602-84-0 |
| Primary source | Rose oil, ylang-ylang, lemongrass; produced endogenously from farnesyl pyrophosphate in cholesterol biosynthesis |
| Key applications | Anti-biofilm, antimicrobial, apoptosis induction (cancer cells), fragrance, skin care |
| Claim strength | Moderate |
| Typical form | Rose/ylang-ylang essential oil constituent; farnesol isolate; endogenous metabolite |
| Buy from Herbuno | Request availability and bulk pricing → |
Name origin: From Farnese — the acacia (Vachellia farnesiana / Acacia farnesiana), named after the Farnese family of Rome. Farnesol is an acyclic sesquiterpene alcohol formed from farnesyl pyrophosphate — a central biosynthetic intermediate in both plant terpene pathways and in mammalian cholesterol/sterol synthesis. Farnesol is thus both a botanical secondary metabolite and an endogenous human metabolite. Traditional use: Rose and ylang-ylang preparations (containing farnesol) have extensive traditional use in Asian and European beauty and medicine traditions. Farnesol itself has not been individually targeted in traditional medicine. Research trajectory: Farnesol has attracted research for: (1) potent anti-biofilm activity against Candida via quorum sensing inhibition — it is a natural quorum-sensing molecule in Candida albicans; (2) apoptosis induction in cancer cell lines via mitochondrial pathway; (3) antimicrobial activity; (4) PPAR-α activation (lipid metabolism). As an endogenous metabolite, it has a distinctive safety profile compared to purely xenobiotic compounds. Commercial source: Not currently available as a standalone extract at commercial supplement scale from Herbuno. Contact Herbuno for availability assessment.
Evidence for Farnesol Applications
Anti-biofilm — Candida quorum sensing inhibition: Farnesol is the primary quorum-sensing molecule in Candida albicans, inhibiting the yeast-to-hypha transition at nanomolar concentrations. Biofilm formation by Candida is a major mechanism of antifungal resistance in chronic infections. Farnesol prevents and disrupts Candida biofilms with efficacy superior to most antifungal drugs for biofilm-specific activity. Claim strength: Moderate (in vitro mechanism well-characterised; human clinical data absent).
Antimicrobial: Farnesol demonstrates activity against S. aureus (including MRSA), streptococci, and oral pathogens, primarily via cell membrane disruption. Anti-biofilm synergy with antibiotics is documented — farnesol at sub-MIC concentrations restores antibiotic sensitivity in biofilm-forming bacteria. Claim strength: Moderate.
Apoptosis induction: Farnesol induces apoptosis in multiple cancer cell lines (leukemia, neuroblastoma, breast, colon) via mitochondrial pathway activation and Ras pathway interference. Its role as a metabolite in the mevalonate/isoprenoid pathway is relevant — it inhibits farnesyl protein transferase, disrupting Ras oncogene activation. Claim strength: Moderate (preclinical only).
PPAR-α activation and lipid metabolism: Farnesol activates PPAR-α (peroxisome proliferator-activated receptor alpha), a nuclear receptor regulating fatty acid oxidation and lipid metabolism. In animal models, reduces hepatic lipid accumulation and plasma triglycerides. Claim strength: Moderate (animal data).
Request availability and bulk pricing →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
No established human supplement dose for farnesol. Oral doses used in animal studies: 25–100 mg/kg for metabolic applications. As a fragrance ingredient, farnesol is used at 0.01–0.5% in finished products. For oral care anti-biofilm applications, farnesol at 0.1–1% in mouthwash formulations is a working concentration based on in vitro effective concentrations. Farnesol is an EU Cosmetics Regulation mandatory fragrance allergen (declaration required above 0.001% in leave-on, 0.01% in rinse-off). Contact Herbuno for farnesol availability.
Frequently Asked Questions — Farnesol
Is farnesol the same as farnesyl pyrophosphate?
Farnesol (farnesyl alcohol) and farnesyl pyrophosphate (FPP) are related but distinct molecules. FPP is the central biosynthetic intermediate — the diphosphate ester of farnesol — from which both squalene (cholesterol precursor) and farnesol are produced. Farnesol is formed by dephosphorylation of FPP. In human cells, FPP accumulates when the mevalonate pathway is inhibited (e.g., by statins), and farnesol produced from this FPP can induce apoptosis. This is one proposed mechanism contributing to statin anti-cancer effects beyond cholesterol lowering.
Why is farnesol important in Candida biology?
Farnesol is the primary quorum-sensing molecule produced by Candida albicans cells. When Candida cell density is low (early colonisation), farnesol levels are low and the organism grows in yeast form (less pathogenic). As cell density increases, farnesol accumulates and inhibits the transition to hyphal (filamentous) form — the more invasive, pathogenic morphology. Farnesol functions as a self-regulating pathogenicity control. Importantly, exogenous farnesol (from supplements or topical applications) can mimic this quorum sensing signal, inhibiting hyphal transition and biofilm formation at concentrations achievable in topical oral care products.
Is farnesol safe as a supplement ingredient?
Farnesol is an endogenous human metabolite (produced in the mevalonate pathway) and is present in many dietary plants and essential oils. As a fragrance, it is used safely at typical cosmetic concentrations. At pharmacological oral doses (far above fragrance use levels), farnesol activates PPAR-α and has metabolic effects; human safety data at supplement doses are not established. Standard precautionary advisory applies.
Can farnesol be used in an oral care product for Candida biofilm prevention?
Yes — this is the most scientifically validated non-fragrance application for farnesol. At 0.1–0.5% in mouthwash formulations, farnesol prevents and disrupts Candida biofilms on oral mucosal surfaces and dental prosthetics (dentures). This application is particularly relevant for immunocompromised patients (HIV/AIDS, chemotherapy, diabetes) who are susceptible to oral candidiasis. The EU fragrance allergen declaration is required at these concentrations in leave-on oral care products.
Related compounds: Nerolidol, Geraniol, Bisabolol, Guaiol
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery